Phathom Pharmaceuticals (PHAT) Depreciation & Amortization (CF) (2019 - 2026)
Phathom Pharmaceuticals (PHAT) reported Depreciation & Amortization (CF) of $110000.0 for Q1 2026, down 37.85% year-over-year from $177000.0 in Q1 2025, and down 14.06% quarter-over-quarter from $128000.0 in Q4 2025.
Phathom Pharmaceuticals (PHAT) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $110000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $110000.0, down 37.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $566000.0 (down 25.33% YoY), and the FY2025 annual result was $633000.0, down 20.38% from the prior year.
- Depreciation & Amortization (CF) retreated to $110000.0 in Q1 2026 per PHAT's latest filing, from $128000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $214000.0 in Q1 2024 and troughed at $110000.0 in Q1 2026.
- A 5-year average of $160764.7 and a median of $168000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) soared 60.16% in 2024, then plunged 37.85% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $168000.0 in 2022, then gained by 10.12% to $185000.0 in 2023, then advanced by 4.32% to $193000.0 in 2024, then plunged by 33.68% to $128000.0 in 2025, then retreated by 14.06% to $110000.0 in 2026.
- Business Quant data shows PHAT's Depreciation & Amortization (CF) at $110000.0 in Q1 2026, $128000.0 in Q4 2025, and $156000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn | 110,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 110,000.00 |
| Mar 31, 2026 | 110,000.00 |
| Dec 31, 2025 | 128,000.00 |
| Dec 31, 2025 | 128,000.00 |
| Sep 30, 2025 | 156,000.00 |
| Sep 30, 2025 | 156,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Dec 31, 2024 | 193,000.00 |
| Dec 31, 2024 | 193,000.00 |
| Sep 30, 2024 | 191,000.00 |
| Sep 30, 2024 | 191,000.00 |
| Jun 30, 2024 | 197,000.00 |
| Jun 30, 2024 | 197,000.00 |
| Mar 31, 2024 | 214,000.00 |
| Mar 31, 2024 | 214,000.00 |
| Dec 31, 2023 | 185,000.00 |
| Dec 31, 2023 | 185,000.00 |